Proteasome inhibitor YSY01A abrogates constitutive STAT3 signaling via down-regulation of Gp130 and JAK2 in human A549 lung cancer cells (vol 8, 476, 2017)

被引：0

作者：

Huang, Wei ^{[1
,2
,3
]}

Yuan, Xia ^{[3
]}

Sun, Ting ^{[3
]}

Fan, Shujie ^{[1
,2
]}

Wang, Jun ^{[1
,2
]}

Zhou, Quan ^{[3
]}

Guo, Wei ^{[3
]}

Ran, Fuxiang ^{[3
]}

Ge, Zemei ^{[4
]}

Yang, Huayu ^{[5
]}

Li, Runtao ^{[4
]}

Cui, Jingrong ^{[3
]}

机构：

[1] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Pharmacol, Beijing, Peoples R China

[2] Peking Union Med Coll, Sch Basic Med, Beijing, Peoples R China

[3] Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing, Peoples R China

[4] Peking Univ, Sch Pharmaceut Sci, Dept Med Chem, Beijing, Peoples R China

[5] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Liver Surg, Beijing, Peoples R China

来源：

关键词：

proteasome inhibitor; YSY01A; STAT3; signaling; protein degradation; non-small cell lung carcinoma;

D O I：

10.3389/fphar.2024.1418274

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页数：3